May 16, 2025 12:33 PM EDTUpdated 02:23 PM
R&D
Cell/Gene Tx

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

Lei Lei Wu

News Reporter

Ryan Cross

Senior Science Correspondent

NEW OR­LEANS — The an­nu­al Amer­i­can So­ci­ety of Gene & Cell Ther­a­py meet­ing felt qui­eter this year, amid fed­er­al fund­ing cuts and a tough time for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

HHS can re­quire ap­proval for drug­mak­ers to ap­ply 340B re­bate mod­els, court rules

A service from the Financial Times